TW200738239A - Stable solid formulation of sertindole - Google Patents

Stable solid formulation of sertindole

Info

Publication number
TW200738239A
TW200738239A TW095130202A TW95130202A TW200738239A TW 200738239 A TW200738239 A TW 200738239A TW 095130202 A TW095130202 A TW 095130202A TW 95130202 A TW95130202 A TW 95130202A TW 200738239 A TW200738239 A TW 200738239A
Authority
TW
Taiwan
Prior art keywords
sertindole
solid formulation
stable solid
pharmaceutical composition
relates
Prior art date
Application number
TW095130202A
Other languages
Chinese (zh)
Inventor
Flemming Enok Olsen
Anne Ravnholdt Christensen
Ken Liljegren
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of TW200738239A publication Critical patent/TW200738239A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a pharmaceutical composition comprising sertindole and a protective agent absorbing radiation with a wavelength below 400 nm. The present invention also relates to the use of sertindole for the preparation of a pharmaceutical composition comprising sertindole and a coating layer comprising said protective agent, such as ironoxide, for the treatment of schizophrenia.
TW095130202A 2005-09-08 2006-08-17 Stable solid formulation of sertindole TW200738239A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200501255 2005-09-08

Publications (1)

Publication Number Publication Date
TW200738239A true TW200738239A (en) 2007-10-16

Family

ID=37697999

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095130202A TW200738239A (en) 2005-09-08 2006-08-17 Stable solid formulation of sertindole

Country Status (17)

Country Link
EP (1) EP1924261A1 (en)
JP (1) JP2009507051A (en)
KR (1) KR20080042102A (en)
CN (1) CN101257906A (en)
AR (1) AR056475A1 (en)
AU (1) AU2006322460A1 (en)
BR (1) BRPI0615630A2 (en)
CA (1) CA2621866A1 (en)
EA (1) EA013167B1 (en)
IL (1) IL189541A0 (en)
MX (1) MX2008002290A (en)
NO (1) NO20081721L (en)
NZ (1) NZ565330A (en)
TW (1) TW200738239A (en)
UA (1) UA97349C2 (en)
WO (1) WO2007065448A1 (en)
ZA (1) ZA200801169B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
WO2010087462A1 (en) * 2009-01-29 2010-08-05 大日本住友製薬株式会社 Orally disintegrating tablet having inner core
FR2943061B1 (en) * 2009-03-13 2011-02-25 Rhodia Operations ORGANOPHOSPHORUS COMPOUNDS, CATALYTIC SYSTEMS COMPRISING THESE COMPOUNDS, AND HYDROCYANATION OR HYDROFORMYLATION PROCESS USING THESE CATALYTIC SYSTEMS
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
HRP20220182T1 (en) 2012-07-16 2022-04-29 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
KR102291860B1 (en) 2013-06-06 2021-08-20 피브로겐, 인크. Pharmaceutical formulations of a hif hydroxylase inhibitor
JP6594303B2 (en) * 2013-11-19 2019-10-23 シガ・テクノロジーズ・インコーポレーテッド Rehydration of micronized Tecobilimat monohydrate
JP2018172361A (en) * 2016-10-14 2018-11-08 大原薬品工業株式会社 Solid preparation containing duloxetine, having improved light stability

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04346929A (en) * 1991-05-22 1992-12-02 Takada Seiyaku Kk Bromocriptine mesylate preparation having stability to light
AU2587297A (en) * 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
NO20081721L (en) 2008-04-08
EA200800774A1 (en) 2008-06-30
CN101257906A (en) 2008-09-03
CA2621866A1 (en) 2007-06-14
BRPI0615630A2 (en) 2016-11-16
KR20080042102A (en) 2008-05-14
NZ565330A (en) 2011-06-30
AR056475A1 (en) 2007-10-10
EP1924261A1 (en) 2008-05-28
IL189541A0 (en) 2008-08-07
EA013167B1 (en) 2010-02-26
AU2006322460A1 (en) 2007-06-14
ZA200801169B (en) 2010-07-28
WO2007065448A1 (en) 2007-06-14
UA97349C2 (en) 2012-02-10
JP2009507051A (en) 2009-02-19
MX2008002290A (en) 2008-03-14

Similar Documents

Publication Publication Date Title
TW200738239A (en) Stable solid formulation of sertindole
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
IL195030A (en) Dpp iv inhibitor formulations
IL186303A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position, pharmaceutical compositions comprising same and use thereof for preparation of a medicament for treating cancer
CL2007003244A1 (en) COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
MX2008011085A (en) Antimicrobial compositions and methods for locking catheters.
JP2006519866A5 (en)
EP2030974A4 (en) Heterocyclic non-nucleoside compounds, their peparation, pharmaceutical composition and their use as antiviral agents
WO2007098128A3 (en) Phenylephrine-containing liquid formulations
WO2008097640A3 (en) Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
CL2007002017A1 (en) COMPOUNDS DERIVED FROM [4,5 '] - BIPIRIMIDINIL-6,4'-DIAMINE; PHARMACEUTICAL COMPOSITION; AND USE AS AN INHIBITOR OF THE ACTIVITY OF CINASA IN CANCER DE VEJIGA, CANCER CERVICAL AND MIELOMA MULTIPLE.
CL2007002261A1 (en) COMPOUNDS DERIVED FROM IMIDAZO [1,2-B] PIRIDAZINA, QUINASA INHIBITORS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OR PREVENTION OF CANCER.
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
WO2008092006A3 (en) Antimicrobial compositions
BRPI0814593A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
WO2008052005A3 (en) Compounds and methods for treating estrogen receptor-related diseases
BRPI0809667A2 (en) COMPOUND, MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND
JO2578B1 (en) 228 Benzimidazole Thiophene Compounds
BRPI0813341A2 (en) "USE OF COMPOUNDS, CURABLE COMPOSITIONS, AND, USE OF CURABLE COMPOSITIONS".
CL2007002207A1 (en) COMPOUNDS DERIVED FROM SULFONYLAMINES; PHARMACEUTICAL COMPOSITION; AND USE OF COMPOUNDS IN THE TREATMENT OF GLAUCOMA.
CL2007002920A1 (en) COMPOUNDS DERIVED FROM 2-AMINOCARBONYLPIRIDINE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
CR10305A (en) "SUBSTITUTED DERIVATIVES OF CHROMANOL AND ITS USE.
BRPI0717369A2 (en) COMPOUND, MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
CL2007003643A1 (en) PHARMACEUTICAL COMPOSITION OF AZIMILIDINE THAT INCLUDES 0.5% TO APPROXIMATELY 2.5% (W / W) OF WATER; AND USE FOR THE TREATMENT OF CARDIAC ARRITMIAS.